Product Information
INVEGA HAFYERA 1,092 MG/3.5 ML is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $4047.7090 per ML under NDC 50458061101. Its NADAC has been published 68 times since Jun 18, 2025.
FDA first approved this application on May 18, 2015.
Strength
1092 mg/3.5mL
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458061101
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
PALIPERIDONE PALMITATEApproval Type
New Drug (NDA)
FDA Application
NDA207946FDA Approved
5/18/2015
On Market Since
8/30/2021
Pharmacological Classes
Price Statistics
The NADAC for INVEGA HAFYERA 1,092 MG/3.5 ML has been published 68 times since Jun 18, 2025, and over the history we have for it it has risen 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4047.7090 per ML |
|---|---|
| All-time high | $4047.7090 (Sep 30, 2026) |
| All-time low | $3916.3960 (Jun 18, 2025) |
| 52-week high | $4047.7090 |
| 52-week low | $3923.2751 |
| Median price | $4018.0637 |
| Average price | $3975.8744 |
| Largest weekly change | +2.4% (Jan 14, 2026) |
| Weeks tracked | 68 |
| Tracking since | Jun 18, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the paliperidone palmitate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paliperidone palmitate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVEGA HAFYERA 1,092 MG/3.5 ML?
The current National Average Drug Acquisition Cost (NADAC) for INVEGA HAFYERA 1,092 MG/3.5 ML, manufactured by Janssen Pharmaceuticals Inc., is $4047.7090 per ML (NDC 50458061101), effective Sep 30, 2026.
How has the price of INVEGA HAFYERA 1,092 MG/3.5 ML changed over time?
Over the history we have for it, the NADAC for INVEGA HAFYERA 1,092 MG/3.5 ML has risen 3.4%. It has been tracked across 68 weekly CMS publications since Jun 18, 2025.
What are the highest and lowest recorded NADAC prices for INVEGA HAFYERA 1,092 MG/3.5 ML?
Since Jun 18, 2025, the NADAC for INVEGA HAFYERA 1,092 MG/3.5 ML has ranged from a low of $3916.3960 (Jun 18, 2025) to a high of $4047.7090 (Sep 30, 2026), with a median of $4018.0637 per ML.
Are there cheaper alternatives to INVEGA HAFYERA 1,092 MG/3.5 ML?
No other NADAC-published product currently shares the active ingredient and strength of INVEGA HAFYERA 1,092 MG/3.5 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures INVEGA HAFYERA 1,092 MG/3.5 ML?
INVEGA HAFYERA 1,092 MG/3.5 ML (NDC 50458061101) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.